Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer

INTRODUCTION: Therapeutically induced androgen deficiency (AD) is a standard treatment for patients with prostate cancer, but it is often associated with various adverse effects (AEs) that may lead to discontinuation. Some AEs may depend on the patient’s health condition, while others may be due to...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Res Rep Urol
Κύριοι συγγραφείς: Tokiwa, Suguru, Shimmura, Hiroaki, Nomura, Shuhei, Watanabe, Ryota, Kurita, Minoru, Yoshida, Naoto, Yamashita, Kaori, Nishikawa, Yoshitaka, Kouzmenko, Alexander, Kato, Shigeaki
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Dove Medical Press 2017
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5724412/
https://ncbi.nlm.nih.gov/pubmed/29264358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/RRU.S146180
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια